Importer of Controlled Substances; Notice of Registration; Meda Pharmaceuticals, Inc., 34072 [2012-13916]
Download as PDF
<![CDATA[
34072
Federal Register / Vol. 77, No. 111 / Friday, June 8, 2012 / Notices
Drug
Schedule
mstockstill on DSK4VPTVN1PROD with NOTICES
Opium, raw (9600) .......................................................................................................................................................................................
Opium extracts (9610) .................................................................................................................................................................................
Opium fluid extract (9620) ...........................................................................................................................................................................
Opium tincture (9630) ..................................................................................................................................................................................
Opium poppy/Poppy Straw (9650) ..............................................................................................................................................................
Poppy Straw Concentrate (9670) ................................................................................................................................................................
Opium, granulated (9640) ...........................................................................................................................................................................
Oxycodone (9143) .......................................................................................................................................................................................
Oxymorphone (9652) ...................................................................................................................................................................................
Pentobarbital (2270) ....................................................................................................................................................................................
Phenazocine (9715) ....................................................................................................................................................................................
Phencyclidine (7471) ...................................................................................................................................................................................
Phenmetrazine (1631) .................................................................................................................................................................................
Phenylacetone (8501) .................................................................................................................................................................................
Piminodine (9730) .......................................................................................................................................................................................
Powdered opium (9639) ..............................................................................................................................................................................
Racemethorphan (9732) ..............................................................................................................................................................................
Racemorphan (9733) ...................................................................................................................................................................................
Remifentanil (9739) .....................................................................................................................................................................................
Secobarbital (2315) .....................................................................................................................................................................................
Sufentanil (9740) .........................................................................................................................................................................................
Tapentadol (9780) .......................................................................................................................................................................................
Thebaine (9333) ..........................................................................................................................................................................................
The company plans to import small
quantities of the listed controlled
substances for the National Institute on
Drug Abuse (NIDA) for research
activities.
Comments and requests for hearings
on applications to import narcotic raw
material are not appropriate. 72 FR 3417
(2007).
In regard to the non-narcotic raw
material, any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances listed in schedule I or II,
which fall under the authority of section
1002(a)(2)(B) of the Act (21 U.S.C.
952(a)(2)(B)) may, in the circumstances
set forth in 21 U.S.C. 958(i), file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than July 9, 2012.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
40 FR 43745–46, all applicants for
registration to import a basic class of
any controlled substances in schedule I
or II are, and will continue to be,
VerDate Mar<15>2010
16:23 Jun 07, 2012
Jkt 226001
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: May 31, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–13920 Filed 6–7–12; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration; Meda
Pharmaceuticals, Inc.
By Notice dated April 2, 2012, and
published in the Federal Register on
April 12, 2012, 77 FR 21998, Meda
Pharmaceuticals, Inc., 705 Eldorado
Street, Decatur, Illinois 62523, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of Nabilone
(7379), a basic class of controlled
substance listed in schedule II.
The company plans to import the
listed controlled substance for
distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a),
and determined that the registration of
Meda Pharmaceuticals Inc. to import the
basic class of controlled substance is
PO 00000
Frm 00070
Fmt 4703
Sfmt 4703
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
consistent with the public interest, and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971. DEA
has investigated Meda Pharmaceuticals
Inc. to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
Dated: May 31, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–13916 Filed 6–7–12; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application;
Rhodes Technologies
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on May 1, 2012,
Rhodes Technologies, 498 Washington
Street, Coventry, Rhode Island 02816,
made application to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
E:\FR\FM\08JNN1.SGM
08JNN1
]]>Agencies
[Federal Register Volume 77, Number 111 (Friday, June 8, 2012)]
[Notices]
[Page 34072]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-13916]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Registration; Meda
Pharmaceuticals, Inc.
By Notice dated April 2, 2012, and published in the Federal
Register on April 12, 2012, 77 FR 21998, Meda Pharmaceuticals, Inc.,
705 Eldorado Street, Decatur, Illinois 62523, made application by
renewal to the Drug Enforcement Administration (DEA) to be registered
as an importer of Nabilone (7379), a basic class of controlled
substance listed in schedule II.
The company plans to import the listed controlled substance for
distribution to its customers.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and 952(a), and determined that the
registration of Meda Pharmaceuticals Inc. to import the basic class of
controlled substance is consistent with the public interest, and with
United States obligations under international treaties, conventions, or
protocols in effect on May 1, 1971. DEA has investigated Meda
Pharmaceuticals Inc. to ensure that the company's registration is
consistent with the public interest. The investigation has included
inspection and testing of the company's physical security systems,
verification of the company's compliance with state and local laws, and
a review of the company's background and history. Therefore, pursuant
to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34,
the above named company is granted registration as an importer of the
basic class of controlled substance listed.
Dated: May 31, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2012-13916 Filed 6-7-12; 8:45 am]
BILLING CODE 4410-09-P
